BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE

Stephanie Ling; Joshua L Bennett; Vanessa J Reid; Saad Ahmed; Mostafa Meshaal Ahmad; Sarah Bennett; Marwan Bukhari; Tom Carver; Mary Chatten; Samantha Cooray; Lucy Craig; Cathy Donaghy; James Galloway; Mark Gibson; Rebecca Heaton; Holly Henderson; Nicola Holroyd; Akhila Kavirayani; Alison Kent; Mariam Malik; Andrew Melville; Tanjina Nasrin; Adlan Wafi Ramli; Alan Rawlings; Emily Rose-Parfitt; Luke Sammut; Ethan S Sen; Demisha Vaghela; Angela Vint; Rosemary Waller; Emma L Williams; Taryn Youngstein; Jean Zhang; Sizheng Zhao; Christopher Holroyd

BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE

Stephanie Ling, Joshua L Bennett, Vanessa J Reid, Saad Ahmed, Mostafa Meshaal Ahmad, Sarah Bennett, Marwan Bukhari, Tom Carver, Mary Chatten, Samantha Cooray, Lucy Craig, Cathy Donaghy, James Galloway, Mark Gibson, Rebecca Heaton, Holly Henderson, Nicola Holroyd, Akhila Kavirayani, Alison Kent, Mariam MalikAndrew Melville, Tanjina Nasrin, Adlan Wafi Ramli, Alan Rawlings, Emily Rose-Parfitt, Luke Sammut, Ethan S Sen, Demisha Vaghela, Angela Vint, Rosemary Waller, Emma L Williams, Taryn Youngstein, Jean Zhang, Sizheng Zhao, Christopher Holroyd^*

^*Corresponding author for this work

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with inflammatory arthritis. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.

Original language	English
Journal	Rheumatology Advances in Practice
Publication status	Accepted/In press - 1 Sept 2025

Cite this

Ling, S., Bennett, J. L., Reid, V. J., Ahmed, S., Ahmad, M. M., Bennett, S., Bukhari, M., Carver, T., Chatten, M., Cooray, S., Craig, L., Donaghy, C., Galloway, J., Gibson, M., Heaton, R., Henderson, H., Holroyd, N., Kavirayani, A., Kent, A., ... Holroyd, C. (Accepted/In press). BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE. Rheumatology Advances in Practice .

@article{01b55405fb674cd7af49a1a546327924,

title = "BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE",

abstract = "This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with inflammatory arthritis. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.",

author = "Stephanie Ling and Bennett, \{Joshua L\} and Reid, \{Vanessa J\} and Saad Ahmed and Ahmad, \{Mostafa Meshaal\} and Sarah Bennett and Marwan Bukhari and Tom Carver and Mary Chatten and Samantha Cooray and Lucy Craig and Cathy Donaghy and James Galloway and Mark Gibson and Rebecca Heaton and Holly Henderson and Nicola Holroyd and Akhila Kavirayani and Alison Kent and Mariam Malik and Andrew Melville and Tanjina Nasrin and Ramli, \{Adlan Wafi\} and Alan Rawlings and Emily Rose-Parfitt and Luke Sammut and Sen, \{Ethan S\} and Demisha Vaghela and Angela Vint and Rosemary Waller and Williams, \{Emma L\} and Taryn Youngstein and Jean Zhang and Sizheng Zhao and Christopher Holroyd",

year = "2025",

month = sep,

day = "1",

language = "English",

journal = "Rheumatology Advances in Practice ",

issn = "2514-1775",

publisher = "Oxford University Press",

}

Ling, S, Bennett, JL, Reid, VJ, Ahmed, S, Ahmad, MM, Bennett, S, Bukhari, M, Carver, T, Chatten, M, Cooray, S, Craig, L, Donaghy, C, Galloway, J, Gibson, M, Heaton, R, Henderson, H, Holroyd, N, Kavirayani, A, Kent, A, Malik, M, Melville, A, Nasrin, T, Ramli, AW, Rawlings, A, Rose-Parfitt, E, Sammut, L, Sen, ES, Vaghela, D, Vint, A, Waller, R, Williams, EL, Youngstein, T, Zhang, J, Zhao, S & Holroyd, C 2025, 'BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE', Rheumatology Advances in Practice .

TY - JOUR

T1 - BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE

AU - Ling, Stephanie

AU - Bennett, Joshua L

AU - Reid, Vanessa J

AU - Ahmed, Saad

AU - Ahmad, Mostafa Meshaal

AU - Bennett, Sarah

AU - Bukhari, Marwan

AU - Carver, Tom

AU - Chatten, Mary

AU - Cooray, Samantha

AU - Craig, Lucy

AU - Donaghy, Cathy

AU - Galloway, James

AU - Gibson, Mark

AU - Heaton, Rebecca

AU - Henderson, Holly

AU - Holroyd, Nicola

AU - Kavirayani, Akhila

AU - Kent, Alison

AU - Malik, Mariam

AU - Melville, Andrew

AU - Nasrin, Tanjina

AU - Ramli, Adlan Wafi

AU - Rawlings, Alan

AU - Rose-Parfitt, Emily

AU - Sammut, Luke

AU - Sen, Ethan S

AU - Vaghela, Demisha

AU - Vint, Angela

AU - Waller, Rosemary

AU - Williams, Emma L

AU - Youngstein, Taryn

AU - Zhang, Jean

AU - Zhao, Sizheng

AU - Holroyd, Christopher

PY - 2025/9/1

Y1 - 2025/9/1

N2 - This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with inflammatory arthritis. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.

AB - This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with inflammatory arthritis. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.

M3 - Article

SN - 2514-1775

JO - Rheumatology Advances in Practice

JF - Rheumatology Advances in Practice

ER -

BIOLOGIC AND TARGETED SYNTHETIC DMARD SAFETY IN INFLAMMATORY ARTHRITIS: BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINE SCOPE

Abstract

Fingerprint

Cite this